Myriad Genetics Receives Patent for High-Definition MRD Assay
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.
Read MorePosted by Andy Lundin | Mar 22, 2024 | Unknown Origin & Other Cancer Types |
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.
Read MorePosted by Andy Lundin | Mar 18, 2024 | Disease States |
A study provides evidence that the novel monoclonal antibody reveals loss of protein function linked to ALS and FTD before symptoms appear.
Read MorePosted by Chris Wolski | Mar 15, 2024 | Miscellaneous |
Data shows how computational indexing combined with a systematic literature review can be used to characterize gene-disease relationships.
Read MorePosted by Andy Lundin | Mar 12, 2024 | Company News |
Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext and CancerNext-Expanded assays.
Read MorePosted by Andy Lundin | Mar 11, 2024 | Cervical (HPV), Cytology |
The ASCCP recognized dual-stain biomarkers as an important tech to determine if an HPV infection is transforming into cervical pre-cancer.
Read More